 9. Patients with an interval of 4 weeks after the discontinuation of therapy with bisphosphonates oral preparations, estrogen preparations, raloxifene, calcitonin preparations, vitamin K preparations, active vitamin D preparations, or ipriflavone preparations, which influence bones 